| Human Molecular Genetics | Pages |
NB4S, a member of the TBC1 domain family of genes, is truncated as a result of a constitutional t(1;10)(p22;q21) chromosome translocation in a patient with stage 4S neuroblastoma
Introduction
Results
Mapping the 1p22 breakpoint
Cloning the gene, NB4S, interrupted by the 1p22 breakpoint
Complete sequencing of the NB4S gene
NB4S homologies
Refining the position of the breakpoint within NB4S
3[prime] RACE to clone the fusion cDNA
Cloning TRNG10
Consequences of the 1;10 translocation
Discussion
Materials And Methods
Cosmid library construction
BAC library screening
5[prime] and 3[prime] RACE
Alu-PCR for generation of specific differential probes
PCR and RT-PCR
Acknowledgements
References
NB4S, a member of the TBC1 domain family of genes, is truncated as a result of a constitutional t(1;10)(p22;q21) chromosome translocation in a patient with stage 4S neuroblastoma
INTRODUCTION
Constitutional chromosome rearrangements have been an important means of identifying genes that are involved in the predisposition to many human genetic disorders, including cancer. Translocations are generally more useful in positional cloning strategies, since the breakpoints usually interrupt the critical genes. Thus, even despite the handful of examples (1-3) where the breakpoints apparently map outside the causative gene, there is still a very realistic expectation that cloning the translocation breakpoints in these patients will reveal the gene responsible for the phenotype. We have used this strategy to investigate a constitutional chromosome translocation in a patient with stage 4S neuroblastoma.
Neuroblastoma is a malignancy arising from primitive neural crest cells that give rise to the adrenal medulla and the sympathetic nervous system. It is the most common extracranial solid tumor in children, accounting for 8-10% of all cases of pediatric neoplasms (4). Histopathologically neuroblastoma can be subclassified into several different groups (5), ranging from the most aggressive form, neuroblastoma, which is comprised entirely of immature neural precursor cells, to ganglioneuroma, which is comprised entirely of mature neural tissue. Ganglioneuroblastoma appears to lie between these two types and is comprised of both the primitive and mature elements in varying proportions. Whether these different manifestations of the disease represent discrete entities or form part of a series of progression stages is not clear. The most important prognostic factor for the patient with neuroblastoma is the extent of the tumor at the time of diagnosis and this has been classified into stages by various groups (6,7). Generally, the higher the stage is the more extensive is the tumor spread. Low stage (1 and 2) tumors do not show the metastatic spread seen in higher stage tumors (3 and 4). Within the spectrum of different presentations of neuroblastoma is a special stage known as stage 4S. This tumor type occurs mainly in children under the age of 1 year and is defined as a small stage 1 or 2 primary tumor but with a very particular pattern of metastatic disease. Metastatic deposits can be found in the skin, presenting as bluish lumps, in the bone marrow, where they form only a small proportion of the nucleated cells, and, most significantly, in the liver, with huge homogeneous involvement. The special feature of stage 4S neuroblastoma is that, despite the metastatic spread and the massive liver involvement, this tumor has the capacity to regress spontaneously. This observation led to the suggestion that stage 4S was a transient failure in differentiation (8). However, some stage 4S tumors, after an initial spontaneous regression, recur as a high grade malignancy and usually proceed to kill the patient (9). The mechanisms that allow for the early metastasis and huge expansion of immature neuroblasts, only to subsequently suffer spontaneous regression, are unknown, but characterizing the genetic events which allow this to occur will undoubtedly provide insights into the molecular mechanisms behind the phenomenon.
In our study of neuroblastoma we have previously described a patient with stage 4S disease and a constitutional, reciprocal, t(1;10)(p22;q21) chromosome translocation (10). This patient survived stage 4S neuroblastoma with no recurrence of the disease. To map the position of the chromosome translocation breakpoints we created somatic cell hybrids which had retained the translocated chromosomes but which had lost the normal homologs. These hybrids allowed us to map the exact position of the chromosomal breakpoints (10). We subsequently concentrated on the short arm of chromosome 1 because of the suggestion from tumor chromosome analysis that genes critical in the development of neuroblastoma were located there. Recently we described a YAC contig across the 1p22 region containing the breakpoint (11). Here we describe molecular cloning and characterization of the genes which are interrupted by this chromosome rearrangement.
RESULTS
Mapping the 1p22 breakpoint
Patient MW was treated successfully for stage 4S neuroblast-oma and carries a constitutional chromosome translocation t(1;10)(p22;q21). Our previous analysis of the t(1;10) chromosome rearrangement using the MWF72 somatic cell hybrid, which contains the derivative chromosome 1 (10), demonstrated that the breakpoint lay within YAC 896B3 (11). When this YAC was fragmented and the resultant YACs analyzed by FISH, it was shown that a 650 kb YAC (F18) crossed the 1p22 breakpoint but an overlapping YAC, which was 400 kb long (F26), did not. Thus, the position of the breakpoint was sub-localized to a 200 kb region. At this time the closest flanking STS markers were D1S424 (distal) and D1S1870E (proximal). A summary of the map in this region is given in Figure
Figure 1. Diagramatic representation of the contig spanning the 1p22 breakpoint. In (A) the location of cosmids prepared from fragmented YAC F18 are shown relative to the four fragmented YACs shown in (B). Where the ends of cosmids were sequenced the orientation of the T7 and T3 ends are indicated. The BAC contig generated using the cosmid end clones and incorporating markers from the database is shown in (C). The ends of only one BAC, 317, were sequenced in order to confirm completion of the contig. Each of the markers on the linear map in (C) were tested for their presence or absence in the MWF72 somatic cell hybrid, which contains 1pter-1p22. Markers shown as (+) lay proximal to the breakpoint and markers shown as (-) lay distal to the breakpoint, which occurs in a 50 kb region between D1S3749 and D1S3747. From our FISH analysis, the 1p22 breakpoint was shown to lie in the region between the endpoints of YACs F26 and F19 (Fig. Using the STS derived from the T7 end of cosmid 97 two BACs, 178 and 373, were isolated. In the same way BACs 317, 35, 103 and 185 were isolated with the STS derived from the T7 end of cosmid 87. The T3 end of cosmid 87 identified BAC 363 in addition to the others already isolated (Fig.
Cloning the gene, NB4S, interrupted by the 1p22 breakpoint
Our previous analysis of the YAC contig in 1p22 (11) identified a NotI fragment in F18, close to the position of the 1p22 breakpoint. Partial sequence analysis of a 9 kb EcoRI fragment containing this NotI site identified homology with the rat Gfi-1 gene (13). We subsequently cloned and sequenced this gene (13) and have now prepared STS from the 5[prime]- (D1S3707E) and 3[prime]-untranslated regions (D1S3708E) of human Gfi-1. Both ends of this gene were shown to lie distal to the 1p22 breakpoint in hybrid MWF 72 and were present in the contig containing cosmids 250-11 and 97, which allowed us to orientate this gene on the chromosome (Fig.
Complete sequencing of the NB4S gene
Using the D1S3649 STS we could establish that NB4S was expressed in human liver and brain cDNA libraries using PCR. This probe identifies a 7.5 kb transcript which is present in virtually all tissue examined. Using this same PCR fragment to screen a liver cDNA library, 22 independent clones were isolated and the longest of these, L7, was 5.2 kb long (Fig.
Figure 2. Relative overlap of the individual clones used to construct the NB4S gene. The dark box (above) represents the open reading frame. The positions of the ends of the individual cDNA clones are shown relative to the 7.4 kb gene. The 5[prime] clone, NB5[prime], was generated by RACE from fetal brain RNA.
NB4S homologies
BLASTN and BLASTP searches of the NB4S nucleotide sequence demonstrated an 88% homology with the mouse EVI-5 gene at both the nucleotide and protein levels over the coding region. However, the 3[prime]-untranslated regions showed less homology, although in specific sub-regions the homology was up to 78%. The BLASTP searches also revealed significant homologies (Fig.
Figure 3. Comparison of the amino acid homologies between NB4S and other TBC1 box gene products. The homologies were confined exclusively to the TBC1 box and the extent of the homologies are indicated as percentages. Homologies were analyzed using the Mega-Align program from DNAStar and BLASTP searches.
Refining the position of the breakpoint within NB4S
In order to characterize the position of the breakpoint more accurately, a series of ESTs were designed throughout the length of the NB4S gene (Fig.
Figure 4. Location of ESTs used in the analysis of the NB4S gene. The position of the intra-exonic primer pairs (see Table 1) used to characterize the position of the breakpoint relative to the BACs in the contig (bold horizontal lines) and cosmids (thin lines above) are indicated. The position of the landmark STS flanking the breakpoint are shown below. The presence (+) or absence (-) of these STS in the MWF72 somatic cell hybrid are indicated at the top. The 1p22 breakpoint lies between EST C2.5 and C3. Table 1.
EST
Position (bp)
GDB no.
UTR3
4861-51129
6900140
UTR2
3008-3186
6900138
UTR1
2447-2603
6900136
C1
2299-2436
6900134
C2
2037-1952
6900132
C2.5
1636-1718
6900147
C3
914-1026
6900130
C4
541-645
6900144
C5
349-468
6900142
EST278249
338-438
NB4S2
141-250
6900148
3[prime] RACE to clone the fusion cDNA
As a result of our analysis of the BACs and the MWF72 hybrid using ESTs derived from within NB4S, we established that the breakpoint was close to EST marker C2.5. RT-PCR analysis of a lymphoblastoid cell line, 556A, which had been established from MW, demonstrated that the 5[prime]-end (EST278) of NB4S was highly expressed, whereas the 3[prime]-end (D1S3649) was not (data not shown). To identify the fusion partner gene on chromosome 10 we performed 3[prime] RACE using the C3 EST from NB4S, which was closest to breakpoint. As a result, a 1.2 kb fragment was amplified. Complete sequencing of this fragment identified the fusion point, at nt 1790 within NB4S (Fig.
Figure 5. DNA sequence at the breakpoint junction fragment of the chimeric mRNA from patient MW beginning at nucleotide position 1563 in NB4S. The breakpoint (arrow) occurs at position 1790 in NB4S and 544 in TRNG10. The location of the primers, B and C, used to identify TRNG10 mRNA are shown, as is the primer pair A and C, used to identify the junction fragment in the chimeric gene. As a result of this fusion an in-frame product is produced with a stop codon 43 bp downstream (indicated by *). The cryptic polyadenylation signal in the TRNG10 gene lies adjacent to primer C (boxed), with the poly(A) tail in the chimeric gene being added 12 bp later. RT-PCR analysis of RNA from normal brain, liver, adrenal gland, thymus and the 556A lymphoblastoid cell line, using primers specific for the chromosome 10 sequence D10S2493E, produced an amplification product of the predicted size in all cases (Fig. Figure 6. RT-PCR analysis of the TRNG10 transcript. Analysis of RNA from a series of normal tissues (above) indicate that the 100 bp TRNG-specific fragment can be detected in reactions which included (+) reverse transcriptase but not in the same samples when reverse transcriptase was excluded (-). poly(A)+ RNA was isolated from the lymphoblastoid cell line (556A) carrying the 1;10 translocation, which also shows the 100 bp fragment. When primers were used which cross the 1;10 translocation breakpoint (below) a PCR product of the predicted size (300 bp) is only generated from the cells carrying the rearrangement.
Cloning TRNG10
RT-PCR analysis indicated that TRNG10 should be present in cDNA libraries from either brain, thymus, adrenal gland or liver. However, despite screening 106 clones from all of these libraries by hybridization, using both the 100 bp PCR product described above and a 3.5 kb EcoRI genomic fragment derived from BAC 20A12 (data not shown), no clones were identified. When northern blots containing RNA from multiple tissues were screened, no expression of TRNG10 could be identified either. These results suggested that the RNA transcript from TRNG10 was either not clonable or present at such low levels that it is not represented in the libraries tested from normal tissues. To establish whether this gene was expressed in tumor cells, we screened a northern blot containing RNA from a series of different cell lines (Fig.
Figure 7. Northern blot analysis using the TRNG10 cDNA. Expression of the 2.8 kb transcript was seen in all the cancer cell lines tested (left) except HeLa. No expression was detected in normal tissues, examples of which are shown from the immune (center) and endocrine (right) systems.
Consequences of the 1;10 translocation
From DNA sequence analysis of both genes involved in the 1;10 translocation, it was possible to reconstruct the events which gave rise to the rearrangement. The 1p22 translocation breakpoint occurs within an intron of NB4S at a splice junction site and the 10q21 breakpoint occurs within the MER22 repeat of TRNG10. As a result, the ORF in the chimeric gene continues through the MER22 repeat at position 524 and reaches a stop codon immediately after the repeat sequence at nt 566 (Fig.
Figure 8. Summary of the composition of the chimeric NB4S/TRNG10 gene. The mRNAs for both genes are shown diagramatically. The relative positions of the ORF (hatched) and UTR (shaded) in NB4S are shown. The positions of the MER22 and ALU repeats in TRNG10 are also shown. The translocation breakpoint in TRNG10 occurs in the MER22 repeat, which is fused in-frame to NB4S. Since a cryptic polyadenylation signal close to the translocation breakpoint is used by the chimeric gene, most of the TRNG10 gene is not represented in the chimera.
DISCUSSION
We have characterized a novel, chimeric gene which is created as a result of a constitutional chromosome translocation in a patient with stage 4S neuroblastoma. This rearrangement results in the truncation of a potential oncogene through its fusion with a gene coding for a non-translated RNA. The fact that this constitutional chromosome translocation fuses two genes to create a novel chimeric gene, together with the fact that the patient develops a highly specific and particularly rare tumor, argues strongly for this rearrangement being causal in the development of the disease. Thus, we have identified two genes which are candidates for involvement in the development of stage 4S neuroblastoma. Whether this chimeric gene results in the generation of a stable oncogene or exhibits a dominant negative effect on the normal counterparts of the gene(s) is not yet clear. Unfortunately, the patient carrying this chromosome rearrangement was treated for her tumor 20 years ago and neither the patient nor her tumor are available for analysis.
The NB4S gene we have identified has some intriguing homologies which potentially implicate it in cell cycle control and/or differentiation. These homologies occur exclusively within the TBC1 domain motif, first identified in the mouse TBC1 gene (18), which is presumed to have a role in regulating cell cycle control and differentiation. Other members of this group include the yeast BUB2 and cdc16 genes, which are also involved in regulation of the cell cycle (19,20). The other homology within the NB4S TBC1 domain is with the TRE-2 oncogene (21). This oncogene was originally isolated from NIH 3T3 cells transfected with Ewings sarcoma tumor DNA (21,22). The oncogene itself is made up of genomic DNA from human chromosomes 5, 18 and 17. The full-length gene consists of two ORFs and at least two alternatively spliced mRNAs called TRE210 and TRE213 (22). Only ORF1 from the TRE210 cDNA can cause cellular transformation. ORF2 has deubiquitinating activity, thereby allowing it to target proteins that are involved in cellular growth and differentiation for degradation by the ubiquitin-dependent pathway (23). It has been suggested that the transforming potential of ORF1 occurs by interfering with the normal product of the TRE-2 gene, thereby switching it off in some way such that the enzyme cannot degrade specific regulatory proteins that are involved in cellular proliferation. The homology between NB4S and the TRE-2 oncogene occurs within the oncogenic ORF1 (TBC1 box). This strongly suggests that NB4S has oncogenic potential as a result of structural rearrangement.
The normal NB4S gene is expressed ubiquitously (data not shown) and the product contains a coiled coil motif at the C-terminus of the protein. This motif implies a protein-protein or protein-DNA binding function. The translocation event in patient MW causes a truncation of NB4S which eliminates the coiled coil motif and presumably, therefore, the function of this motif. Coils are formed when right handed [alpha]-helices wrap around each other (24) and several different types of coil motifs have been identified to date, which include two, three and four stranded coils. Qian et al. (25), for example, showed that PKD1 interacts with PKD2 through a coiled coil motif and the interaction may regulate the activity of PKD2. Therefore, coil motifs seem to be involved in cellular protein-protein interactions, suggesting that NB4S may bind to other proteins within the cell and regulate their activity. Thus the 1;10 translocation may affect the ability of NB4S to interact with other components involved in the cell cycle, thereby leading to misregulation. In this respect NB4S may be functioning as a tumor suppressor gene and its disruption leads to oncogenic transformation through dominant negative interactions.
The highly specific expression profile of TRNG10 also implicates it in tumorigenesis. So far, after screening a large number of commercially available northern blots containing poly(A) RNA, we have been unable to detect expression of this gene in any normal tissue. In contrast, a number of different tumorigenic cells lines show reasonable levels of expression. Since TRNG10 could be detected at low levels in most normal RNA samples tested using RT-PCR, it appears that TRNG10 is specifically activated, or more probably up-regulated or stabilized, in transformed cells. The stabilization theory is supported by our observations of the distribution of the transcript. Thus, although we could detect the TRNG10 transcript in RNAs from different tissues, we could not isolate the gene from the corresponding cDNA libraries, possibly suggesting that the TRNG10 is highly unstable. Xu et al. (26) found that the first step in mRNA turnover is deadenylation, which is directed by RNA destabilization elements. The RNA first undergoes deadenylation, with very little degradation, whereafter the RNA is quickly degraded. It is possible that this transcript is missing in most cDNA libraries and lacks a poly(A) tail in other libraries because of its rapid turnover. Since stable transcripts were only found in a leukemia cDNA library and expression only occurs within transformed cell lines, this suggests that TRNG10 could be a gene that is activated as a consequence of oncogenic transformation. A similar situation was reported by Askew et al. (27) for the non-coding HIS-1 gene. In this case retroviral insertion activated this gene and northern blot analysis demonstrated transcripts only in transformed cell lines and not normal tissues.
The fact that TRNG10 could be detected in normal brain, liver, thymus, heart and adrenal glands by RT-PCR demonstrates that it is transcribed, but whether it is translated is not clear. Northern blot analysis showed a single full-length TRNG10 transcript that is 2.8 kb long, the same length that is detected in genomic DNA. However, there were no characteristic gene motifs within the sequence, no significant ORF and no obvious exon/intron structure. It is possible, therefore, that TRNG10 is one of the growing number of structural RNA genes that are transcribed but not translated. These include NTT (28), IPW (29), H19 (30) and Xist (31). These genes vary in size from 2.2 (IPW) to 17 kb (NTT), contain no ORFs and frequently contain repeat motifs such as Alu, MER and Lines. They also have very specific expression patterns. Both IPW and Xist have very large exons and small introns. The NTT gene does not have an intron/exon structure at all and is apparently only expressed in activated human CD4+ T cells. TRNG10 could only be detected on northern blots containing RNA from tumor cells so far and does not have exon/intron structure either. The translocation occurs within the middle of TRNG10 within a second MER22 repeat and causes a truncation of NB4S. RT-PCR analysis only detected expression of the unique fusion gene in the 556A lymphoblastoid cell line. Since only the NB4S-TRNG10 fusion product could be detected but not the TRNG10-NB4S fusion product, it appears that NB4S-TRNG10 is the oncogenic product generated by the 1;10 translocation. The RT-PCR analysis suggests that the truncated gene is overexpressed. The possibility that this truncation event results in stabilization of the truncated NB4S transcript is supported by the fact that the normal NB4S gene has 12 destabilizing sequences (AUUUA), as described by several authors (26,32), within the UTR which are lost as a result of the translocation. The truncated, chimeric gene lacks these motifs, which could make the transcript more stable, thereby contributing to its overexpression. There is evidence that repetitive elements can inactivate genes by splicing themselves into the coding regions (reviewed in ref. 33). These events usually result in truncation of the protein by introducing stop codons. Thus, the factor XI gene responsible for hemophilia B and the cholinesterase gene have been shown to be inactivated by insertion of Alu repeats into the coding region. In other cases, as we have seen in NB4S, the repetitive sequences can actually contribute extra codons to the host protein (33). In our case the rearranged NB4S coding region is extended by 42 bp derived from the MER22 repeat fused in-frame before the termination signal. This analogy suggests that NB4S is functionally inactivated as a result of the truncation. These various repetitive elements, as in NB4S, have also been shown to contribute cryptic poly(A) signals. Thus, as a result of insertion of an L1 element into the thymidylate synthase gene, for example, a poly(A) tail is added at the translational stop codon (34), with exclusion of the original 3[prime]-untranslated region.
NB4S is the human homolog of the mouse EVI-5 gene (35). EVI (ectopic viral integration)-like genes are usually referred to as proto-oncogenes and they tend to be activated by chromosomal rearrangements. The EVI-1 gene in humans can be activated by chromosomal rearrangements involving either the 5[prime]- or 3[prime]-ends of the gene (36). The gene can also be activated as part of a fusion product. At present, it is not known whether proviral integration into the mouse EVI-5 gene, which occurs within the coiled coil motif, causes overexpression of the gene or whether integration causes loss of function of the gene through production of a truncated protein (35). The fact that the various homologs of NB4S are susceptible to activation/deactivation through chromosomal rearrangement strongly supports the role of the constitutional rearrangement in the development of neuroblastoma.
Another line of evidence strongly implicating NB4S in the development of neuroblastoma comes from transgenic studies in mice. Weiss et al. (37) used the tyrosine hydroxylase promoter, which is expressed in cells migrating off the neural crest during development, to overexpress the MYCN oncogene, which is amplified in many cases of neuroblastoma, in the neural crest cells of transgenic mice. When the karyotypes from these tumors were examined several chromosomes were consistently involved in rearrangements, suggesting sites of genes which contribute to the development of neuroblastoma. One of the most frequently rearranged chromosomes was mouse chromosome 5. We (13) and others (35,38-40) recently established a new region of synteny between human chromosome 1p22 and mouse chromosome 5. So far, the mouse genes that are part of this syntenic group are GFI-1 and EVI-5 and the region of mouse chromosome 5 that is frequently rearranged in MYCN neuroblastomas is exactly in the region of synteny (37).
Recent gene map data available from NCBI have mapped another member of the TRE family, TRE-17, within the consensus region on chromosome 17q11-12, frequently the site of chromosome translocation breakpoints in neuroblastoma. Thus, Laureys et al. (41) described a patient with stage 4 neuroblastoma who carried a t(1;17)(p36;q11-12) translocation. Other reports have described translocations involving breakpoints in chromosome 17p12 in tumors (42). Although the genes involved in these rearrangements have not been described, if they involve members of the TRE family this would provide a further indication that this family of genes plays a part in the development of neuroblastoma.
The genetic basis of neuroblastoma is proving to be very complex and, with the possible exception of MYCN (37), no candidate genes related to neuroblastoma tumorigenesis have been described to date. The NB4S and TRNG10 genes, therefore, because of their constitutional rearrangement in a patient with stage 4S disease, offer exciting possibilities to study their role in tumorigenesis.
MATERIALS AND METHODS
Cosmid library construction
Yeast chromosomes were prepared in agarose plugs as described previously (11). Plugs were melted at 65°C for 15 min in 1× restriction enzyme buffer. The liquified plugs were then transferred to 37°C for 5 min. SauIIIa (0.1 U; Gibco BRL) was added to the cooled liquified plugs and digestion allowed to proceed for 2-5 min. Digestion was then stopped by adding EDTA to a final concentration of 25 mM and heating to 65°C for 15 min. The partially digested DNA was allowed to cool to room temperature and purified by phenol/chloroform extraction. The DNA was then precipitated with sodium acetate and ethanol and then resuspended to 0.5 µg/µl in sterile distilled water. The partially digested DNA was cloned into the Supercos vector (Stratagene) according to the manufacturer's protocol. Human clones were identified by hybridization using total human genomic DNA.
BAC library screening
BACs were isolated from the Research Genetics human BAC library, which was screened using STS markers according to the distributor's protocols. All clones were plated out onto LB agar plates containing 12.5 µg/ml chloramphenicol. Single clones were isolated and analyzed by colony PCR (11). Positive clones were then grown up in LB broth containing the appropriate antibiotic and DNA prepared using the alkali lysis procedure. BAC clones were sized by pulsed field gel electrophoresis after digestion with NotI using the following parameters; 1% agarose gel run at 6 V/cm for 17 h with a switch time of 6.7-13.5 s.
5[prime] and 3[prime] RACE
In order to clone the 5[prime]-end of the NB4S gene, the 5[prime] RACE system and protocol from Gibco was followed. Aliquots of 2 µg total RNA from human brain (Clontech) were used for first round synthesis with the gene-specific primer GSP1 (5[prime]-GTAACGATCTTGAATGGAC-3[prime]; nt 645-626). GSP2 (5[prime]-TTCTACATGCGTTTTTCTTC-3[prime], nt 468-448) was used in the first nested primer reaction and GSP3 (5[prime]-CTAAGAAACCCTTCTTAACAAT-3[prime], nt 438-416) was used to generate the 5[prime]-specific product.
For the isolation of sequences fused to the NB4S gene we carried out 3[prime] RACE on RNA extracted from the lymphoblastoid cell line 556A containing the constitutional translocation. Reverse transcription was performed using the 3[prime] RACE kit from Gibco. The first round of amplification was started with a GSP from the NB4S sequence nt 541-559 (5[prime]-GCAGTGCACAAAGTATGCC-3[prime]). A nested PCR reaction was performed using GSP2 at position nt 914-933 (5[prime]-TCTTCCAGAGCTCTTTGTAC-3[prime]) in order to generate a specific product. The 3[prime]-end of the TRNG10 sequence was also cloned using the 3[prime] RACE procedure. GSP1 at nt 2182-2222 (5[prime]-CAATGCAAAGGTTGTCTGTCC-3[prime]) was used in the first round amplification and GSP2 at nt 2215-2236 (5[prime]-GACTCATTTGTCTAAGTGGGCC-3[prime]) was used to obtain a specific product. RACE products were cloned into the pGem-T vector (Promega) and transformed into JM109 competent cells (Promega). Clones were analyzed and sequenced using T7 and SP6 primers.
Alu-PCR for generation of specific differential probes
Fresh colonies from individual fragmented YAC clones were amplified directly in 100 µl PCR reaction buffer using the ALU III and ALU IV repeat primers (43). The amplification was carried out for 40 cycles using the following parameters, 94°C for 1 min, 55°C for 1 min and 72°C for 3 min. Following amplification, 50 µl of the reaction were run on a 1.5% low melting agarose gel until the bands were well separated. The banding patterns between different overlapping YAC clones were compared and bands that were present exclusively in the larger clones allowed them to be mapped within the YAC. These bands were cut out of the gel for use as probes for hybridization. PCR reactions were repeated twice to confirm that the banding patterns were consistent. All 32P-labeled probes were competed at 65°C for 15 min with human placental DNA at 2.5 µg/µl before hybridization.
PCR and RT-PCR
RNA was isolated using Trizol reagent. Samples of 1-2 µg total RNA or 500 ng mRNA were reverse transcribed using Superscript II (Gibco) and random hexamers (Promega). All PCRs were performed using Taq polymerase and the buffer supplied by Gibco with 0.2 mM dNTPs and 0.2 µm primers. PCR products were analyzed on 3% agarose gels.
ACKNOWLEDGEMENTS
We are grateful to the CCF core sequencing facility for their assistance. This work was supported by NIH grant RO1 NS35791 and the Rose-Ella Burkhardt Endowment Fund.
REFERENCES
This article has been cited by other articles:
This page is run by Oxford University Press, Great Clarendon Street, Oxford OX2 6DP, as part of the OUP Journals
Comments and feedback: www-admin{at}oup.co.uk
Last modification: 8 Jun 1998
Copyright©Oxford University Press, 1998.
![]()
CiteULike
Connotea
Del.icio.us What's this?
![]()
![]()

![]()
![]()
![]()
K. Vandepoele, V. Andries, and F. van Roy
The NBPF1 Promoter Has Been Recruited from the Unrelated EVI5 Gene Before Simian Radiation
Mol. Biol. Evol.,
June 1, 2009;
26(6):
1321 - 1332.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
K. V. Prasanth and D. L. Spector
Eukaryotic regulatory RNAs: an answer to the 'genome complexity' conundrum
Genes & Dev.,
January 1, 2007;
21(1):
11 - 42.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
I. M. Veltman, L. A. Vreede, J. Cheng, L. H.J. Looijenga, B. Janssen, E. F.P.M. Schoenmakers, E. T.H. Yeh, and A. G. van Kessel
Fusion of the SUMO/Sentrin-specific protease 1 gene SENP1 and the embryonic polarity-related mesoderm development gene MESDC2 in a patient with an infantile teratoma and a constitutional t(12;15)(q13;q25)
Hum. Mol. Genet.,
July 15, 2005;
14(14):
1955 - 1963.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
G. Troen, V. Nygaard, T.-K. Jenssen, I. M. Ikonomou, A. Tierens, E. Matutes, A. Gruszka-Westwood, D. Catovsky, O. Myklebost, G. Lauritzsen, et al.
Constitutive Expression of the AP-1 Transcription Factors c-jun, junD, junB, and c-fos and the Marginal Zone B-Cell Transcription Factor Notch2 in Splenic Marginal Zone Lymphoma
J. Mol. Diagn.,
November 1, 2004;
6(4):
297 - 307.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
M. S. Shin, T. N. Fredrickson, J. W. Hartley, T. Suzuki, K. Agaki, and H. C. Morse III
High-Throughput Retroviral Tagging for Identification of Genes Involved in Initiation and Progression of Mouse Splenic Marginal Zone Lymphomas
Cancer Res.,
July 1, 2004;
64(13):
4419 - 4427.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
H. Shen, T. Suzuki, D. J. Munroe, C. Stewart, L. Rasmussen, D. J. Gilbert, N. A. Jenkins, and N. G. Copeland
Common Sites of Retroviral Integration in Mouse Hematopoietic Tumors Identified by High-Throughput, Single Nucleotide Polymorphism-Based Mapping and Bacterial Artificial Chromosome Hybridization
J. Virol.,
December 20, 2002;
77(2):
1584 - 1588.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
M. L. Brandi, R. F. Gagel, A. Angeli, J. P. Bilezikian, P. Beck-Peccoz, C. Bordi, B. Conte-Devolx, A. Falchetti, R. G. Gheri, A. Libroia, et al.
CONSENSUS: Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2
J. Clin. Endocrinol. Metab.,
December 1, 2001;
86(12):
5658 - 5671.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
T. Nakamura, Y. Yamazaki, Y. Saiki, M. Moriyama, D. A. Largaespada, N. A. Jenkins, and N. G. Copeland
Evi9 Encodes a Novel Zinc Finger Protein That Physically Interacts with BCL6, a Known Human B-Cell Proto-Oncogene Product
Mol. Cell. Biol.,
May 1, 2000;
20(9):
3178 - 3186.
[Abstract]
[Full Text]
![]()
![]()
![]()

![]()
![]()
![]()
C. Heppner, M. Reincke, S. K. Agarwal, P. Mora, B. Allolio, A. L. Burns, A. M. Spiegel, and S. J. Marx
MEN1 Gene Analysis in Sporadic Adrenocortical Neoplasms
J. Clin. Endocrinol. Metab.,
January 1, 1999;
84(1):
216 - 219.
[Abstract]
[Full Text]
![]()
This Article ![]()
![]()
Abstract
![]()
FREE Full Text (PDF)
![]()
Alert me when this article is cited
![]()
Alert me if a correction is posted
![]()
Services ![]()
![]()
Email this article to a friend
![]()
Similar articles in this journal
![]()
Similar articles in ISI Web of Science
![]()
Similar articles in PubMed
![]()
Alert me to new issues of the journal
![]()
Add to My Personal Archive
![]()
Download to citation manager
![]()
Search for citing articles in:
ISI Web of Science (36)
![]()
Request Permissions ![]()
Google Scholar ![]()
![]()
Articles by Roberts, T.
![]()
Articles by Cowell, J. K.
![]()
Search for Related Content
![]()
PubMed ![]()
![]()
PubMed Citation
![]()
Articles by Roberts, T.
![]()
Articles by Cowell, J. K.
![]()
Social Bookmarking ![]()
![]()
What's this?